Dr. Aldridge is an engineer and a biologist who specializes in combining live-cell microscopy and mathematical modeling to create intuitive descriptions of complex cell biology. Dr. Aldridge is an Assistant Professor in the Department of Molecular Biology and Microbiology and Department of Biomedical Engineering at Tufts University. The Aldridge lab seeks to bring a quantitative framework to understand tuberculosis infection and drug response at single-cell resolution.
Michael Baym is an Assistant Professor of Biomedical Informatics at Harvard Medical School. Dr. Baym’s research is centered around the problem of antibiotic resistance, at the intersection of experimental, theoretical and computational techniques. His work ranges from understanding the basic mechanisms of evolution to the development of algorithms for computation on massive biological datasets.
Dahlene Fusco is an Instructor in Medicine at Harvard Medical School and Director of the MGH Revere Viral Hepatitis Clinic (HBV and HCV). Dr. Fusco’s group works on characterization of host-virus interactions with a focus on how host interferon suppresses viral infections through modification of genetic, protein, and metabolic intracellular patterns. Using this information, she and her team are working to establish relatively immunocompetent mouse models for flaviviral infections.
Dr. Goel is a physician-scientist at the Dana-Farber Cancer Institute. His research is focused on understanding mechanisms of resistance to existing therapies for breast cancer, and ultimately aims to develop new therapeutic combinations which can be moved into early phase clinical trials. He works extensively with genetically engineered mouse models of breast cancer and also has a strong interest in the immunological aspects of the disease. In addition to his research, Dr. Goel sees breast cancer patients at the Dana-Farber and leads clinical trials which are directly related to his laboratory studies.
Dr. Nathanael Gray is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Cancer Biology at Dana Farber Cancer Institute. His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance. He has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development.
Dr. Gygi is a Professor of Cell Biology at Harvard Medical School. Dr. Gygi is a pioneer in mass spectrometry-based proteomics. His contributions to phosphorylation and then ubiquitylation analysis have revolutionized the study of these modifications. Currently, Dr. Gygi spends all of his time creating and optimizing multiplexing strategies.
Dr. Izar is a physician-scientist at Dana-Farber Cancer Institute and the Broad Institute. His research is focused on using single-cell RNA-sequencing and highly multiplexed imaging of patient specimens to elucidate mechanisms of resistance to immune checkpoint inhibitors and MAPK pathway inhibitors, and tumor heterogeneity in melanoma. Furthermore, he developed patient-derived models to study cell non-autonomous mechanisms of treatment resistance.
Marc Kirschner, Founding Chair of Systems Biology
Dr. Kirschner is founding chair of the Department of Systems Biology and John Franklin Enders University Professor of Systems Biology. Dr. Kirschner¹s laboratory investigates: regulation of the cell cycle, the role of cytoskeleton in cell morphogenesis, and mechanisms of establishing the basic vertebrate body plan.
Dr. Lahav is a Professor of Systems Biology at Harvard Medical School. Her lab uses mathematical modeling and imagine to study cellular dynamics with a particular focus on the p53 tumor suppressor.
Dr. Loscalzo is the Hersey Professor of the Theory and Practice of Physic at Harvard Medical School, Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women’s Hospital, and Vice Director of the Brigham Biomedical Research Institute. Currently, his lab is chiefly interested in the vascular biology of endothelial cells and platelets.
Dr. Marks is an Assistant Professor of Systems Biology. She is a computational biologist interested in how to read the genome and interpret its variation. Recently, she has used evolutionary couplings determined from genomic sequencing to accurately protein 3D structure from sequences alone, including the experimentally challenging transmembrane proteins. Her lab aims to predict alternative conformations and plasticity of proteins, and the consequences of protein genetic variation on pharmacological intervention.
Tim Mitchison, Deputy Director
Timothy J. Mitchison is a Professor in HMS Dept. of Systems Systems Biology who studies the spatial organization of microtubules and actin filaments and has been at the forefront of using novel optical methodologies to understand drugs that affect the cytoskeleton.
Dr. Rubin is a Professor of Stem Cell and Regenerative Biology at Harvard University and a Director of Translational Medicine of the Harvard Stem Cell Institute. Much of his effort is devoted to identifying therapeutics for orphan neural disorders such as Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis, using new kinds of stem cell-based screens. His lab is also interested in methods of reversing aging-associated neurodegeneration.
Dr. Sarosiek is an Assistant Professor of Radiation Biology at Harvard T.H. Chan School of Public Health. Dr. Sarosiek has focused his studies on understanding how the regulation of apoptosis (programmed cell death) in healthy as well as diseased cells affects their sensitivity to damage or stress. Currently, his laboratory is developing novel agents that can be used to directly modulate cell death in vivo. These agents may potentially be useful for the treatment of cancers and neurodegenerative diseases or prevention of healthy tissue toxicity from environmental, medical and pathological factors. Read more at sarosieklab.org.
Dr. Shah is an Associate Professor of Systems Biology and Director of the Laboratory for Cellular Systems Biology and Molecular Imaging in the Renal Division at Brigham and Women’s Hospital. His lab applies advanced approaches in photonics, imaging and computational modeling to better understand cellular dynamics and the cell cycle.
Dr. Silver is a Professor of Systems Biology. The Silver Lab works at the interface between systems and synthetic biology to design and build biological systems in both mammalian and prokaryotic cells. Some current projects include analysis of cells that remember past events, cell-based computation and therapeutics, and metabolic engineering for bio-energy and sustainability.
Peter K. Sorger, Director
Peter Sorger is a Professor in HMS Dept. of Systems Biology and MIT Department of Biological Engineering. His laboratory uses experimental, computational and pharmacological methods to study mammalian signal transduction networks in cancer and inflammatory disease.
Jerrold Turner is a Professor of Pathology and Medicine at Harvard Medical School and Brigham and Women’s Hospital. Dr. Turner is a leader in defining regulation of mucosal barrier function, mechanisms of barrier regulation, and the impact of such regulation on mucosal pathobiology. His laboratory currently focuses on problems ranging from fundamental questions in tight junction cell biology to development of therapeutic interventions to modulate the mucosal barrier.
Dr. Weissleder is the Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School, Director of the Center for Systems Biology at Massachusetts General Hospital (MGH), and Attending Clinician (Interventional Radiology) at MGH. Dr. Weissleder’s research interests include the development of novel high resolution molecular imaging systems, tools for early disease detection, and modeling methods for systems analysis. His work has led to a number of novel sensing technologies, imaging approaches and advanced clinical trials.